January 8, 2019

FierceBiotech Executive Breakfast & Panel Discussions at J.P. Morgan 2019

The Fairmont | Grand Ballroom | San Francisco

EVENT IS SOLD OUT!

About

Join FierceBiotech during the J.P Morgan Healthcare Conference with two panel discussions, a full breakfast, and networking at The Fairmont in San Francisco.

Attendees will have the opportunity to engage with speakers and panelists, expand their knowledge on the biotech and healthcare industries, and network with peers and colleagues.

Event Schedule:
7:00AM-7:45AM // Registration, Breakfast Buffet, and Networking
7:45AM-9:15AM // Panel One - Rewiring R&D: The Promises of Digital, AI, and Machine Learning for Biotech Research
9:15AM-9:45AM // Coffee Break and Networking
9:45AM-11:00AM // Panel Two - Challenges and Solutions Around the Drug Pricing Debate

View panel and speaker information below.

Speakers

Andrew Allen M.D., Ph.D.

Co-Founder, President, and CEO // Gritstone Oncology
Dr. Andrew Allen is a co-founder of Gritstone Oncology (NASDAQ:GRTS) and serves as president, CEO and a member of the board. Previously he was a co-founder of Clovis Oncology and CMO at Pharmion Corporation (sold to Celgene Corporation for $2.9 billion). He serves on the board of directors of Epizyme, Sierra Oncology and Revitope Oncology. Dr. Allen received his MD from Oxford University and a Ph.D. in immunology from Imperial College, London.

Percival Barretto-Ko

President, Americas Operations // Astellas
Percival Barretto-Ko is president, Astellas Americas. In this role, he has responsibility for the company's operations across the Americas region of Astellas, a company dedicated to improving the health of people around the world through the provision of innovative pharmaceutical products across multiple therapeutic areas.

Previously, Barretto-Ko was SVP, international, where he led Astellas’ operations in over 20 markets. In 2011, he served as SVP, corporate strategy and government affairs. Before joining Astellas, Barretto-Ko held increasingly senior commercial positions with Roche in the United States and United Kingdom.

Barretto-Ko serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA). Barretto-Ko earned a B.S. in biological sciences with honors from Cornell University, an MBA from Yale School of Management and an M.S. from MIT Sloan School of Management, where he served as a Sloan Fellow.

Fritz Bittenbender

Senior Vice President, Government Affairs // Genentech
As Senior Vice President of Government Affairs at Genentech, Fritz oversees Federal Government Affairs, Patient Advocacy, Public Policy and Reimbursement, and State Government Affairs. He previously served as Executive Vice President of Public Affairs at the Biotechnology Innovation Organization (BIO). He has significant biopharmaceutical industry experience, having served as Vice President of Global Public Affairs at Cephalon and President of the CephalonCares Foundation. Prior to Cephalon, he was the Deputy Chief of Staff to former Pennsylvania Governor Tom Ridge.  

Alexis Borisy

Partner // Third Rock Ventures
Alexis Borisy is a biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Alexis joined Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies.

Alexis’ undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis is a trustee of the Boston Museum of Science, is a co-founder and former chairman of FORMA Therapeutics, and serves on the board of the National Venture Capital Association.

Ruud Dobber

Executive Vice President, North America // AstraZeneca US
Ruud leads commercial operations in North America as a member of the AstraZeneca Senior Executive Team. Ruud was previously EVP, Europe; Regional VP of the European, Middle East and African division; and Regional VP for Asia Pacific.  He served on the Board of the European Trade Group EFPIA and Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Holding a doctorate in immunology, Ruud began his career as a scientist focused on immunology and aging.

Kevin Julian

Senior Managing Director, Life Sciences // Accenture
Kevin Julian is a senior managing director leading Accenture's global Applied R&D Services and Intelligent Patient Solutions groups. He is responsible for industry-specific solutions and platforms across Accenture’s strategy, consulting, technology, digital and operations businesses, helping life sciences clients deliver better patient outcomes and improve business performance. Prior to joining Accenture in 1989, Kevin earned a bachelor’s degree in Systems Engineering from the University of Pennsylvania.

Daphne Koller

CEO // Insitro
Daphne Koller is CEO and Founder of Insitro, a company applying machine learning to drug development. Daphne was a Computer Science Professor at Stanford, Co-Founder and Co-CEO of Coursera, and Chief Computing Officer of Calico. Daphne was one of TIME Magazine’s 100 most influential people, and is a MacArthur Fellow, a member of the National Academy of Engineering, and a Fellow of the American Academy of Arts and Sciences and the International Society of Computational Biology. 

Kristi Martin

Senior Vice President // Waxman Strategies
Kristi L. Martin is a senior vice president at Waxman Strategies, a mission driven consulting firm focusing on the areas defining the next generation of global progress – health, the environment and technology. Prior to joining Waxman, Kristi served in the U.S. Department of Health and Human and Human Services where she was senior advisor coordinating cross-cutting Departmental initiatives. 

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Saurabh Saha

Global Head of Translational Medicine // Bristol-Myers Squibb
Saurabh Saha, M.D. Ph.D. is Senior Vice President R&D and Global Head of Translational Medicine at Bristol-Myers Squibb. Previously, Dr. Saha was a Venture Partner at Atlas Venture, CMO of Synlogic, and CEO of Delinia until its sale to Celgene in 2017. Earlier in his career, Dr. Saha was a consultant at McKinsey and head of the New Indications Discovery at Novartis. He received an M.D.-Ph.D. from Johns Hopkins and is an alumnus of Harvard Business School, Oxford, and Caltech.

Glen Stettin, MD

Chief Innovation Officer // Express Scripts
Glen Stettin, MD, heads up clinical products, Consumerology, the Therapeutic Resource Centers, specialty, channel, trend and formulary management, as well as integrated health solutions.

Dr. Stettin earned his bachelor and medical degrees through Lehigh University and the Medical College of Pennsylvania.

Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident at Moffitt-Long Hospital, fellow in cardiology and Robert Wood Johnson Foundation Clinical Scholar at UCSF and Stanford University.

John Tsai

Head of Global Drug Development // Novartis
John Tsai, M.D., has been Head of Global Drug Development and Chief Medical Officer for Novartis since May 1, 2018. He is a member of the Executive Committee of Novartis.

Dr. Tsai joined Novartis from Amgen Inc., where he was Chief Medical Officer and Senior Vice President of Global Medical, overseeing all clinical and medical functions across multiple sites worldwide. Before joining Amgen in 2017, he spent 11 years at Bristol-Myers Squibb Co. (BMS), most recently as global head of clinical development for marketed products. During his time at BMS, Dr. Tsai also served as a full development team lead in oncology, Head of Worldwide Medical, Chief Medical Officer for Europe, Vice President of US Medical, and Vice President of Cardiovascular Medical. Prior to BMS, he was a Cardiovascular Group Leader at Pfizer, Inc. He started his career as an electrical engineer at General Electric Co.

Dr. Tsai holds a medical degree from the University of Louisville School of Medicine in the United States. He received a Bachelor of Science in electrical engineering from Washington University in St. Louis, also in the US.

Stephen J. Ubl

President and Chief Executive Officer // PhRMA
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. He is routinely recognized as one of Washington’s most effective advocates, and, in 2018, was named for the third year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.”

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Tony Wood

SVP Medicinal Science and Technology // GSK
Tony Wood joined GSK in October 2017 and is a member of the R&D Leadership Team, reporting to Hal Barron, President, R&D.

Tony was previously head of Worldwide R&D’s Medicinal Sciences at Pfizer, and prior to that held roles of increasing seniority in chemistry and medicinal sciences across a range of therapy areas. Tony He was the co-recipient of the ACS Heroes of Chemistry Prize, the Prix Galien USA and Scrip Awards in 2008, and the PhRMA Discoverers Award in 2010. He is a Fellow of the Academy of Medical sciences.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Moderator: Amirah Al Idrus

Editor // FierceBiotech
Amirah Al Idrus is an editor with the FierceMarkets Life Sciences group covering medtech and biotech research. Before joining Fierce, Amirah completed a master's degree in journalism at the University of Maryland, where she concentrated in online and multimedia journalism. She has covered issues ranging from Maryland politics and local business to finance in state prisons. When she's not working, Amirah spends her time playing rugby, running around D.C., visiting museums, and baking (and eating) pies. She can be reached at [email protected].

Moderator: Carly Helfand

Senior Editor // FiercePharma
Carly Helfand is a news editor with FierceMarkets' Life Sciences group, writing for FierceVaccines, FiercePharma and FiercePharmaMarketing. Carly got her start covering pharma while earning her master's at Northwestern University's Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post's Wonkblog and Cape Town's Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at [email protected].

AGENDA

REWIRING R&D: THE PROMISES OF DIGITAL, AI, AND MACHINE LEARNING FOR BIOTECH RESEARCH
7:45AM-9:15AM


Digital health has long been a buzz word in biopharma. We think of new apps that claim to detect certain skin cancers, interacting with your doctor on a smartphone 24/7, or accessing your patient records from your own devices in your own time.

What we don’t always think about is how digital is helping research. A number of new companies have launched that aim at speeding up clinical trials or retaining those already signed up—two major issues for biopharma that can add to costs and cause delays. Big Data can also be leveraged to find the right patients for the right trials, drugs, and devices. Artificial intelligence and machine learning are supporting biomedical research as many look to make good on the promises of high-tech, futuristic ideas becoming a reality in people’s healthcare.

But where there is promise, there has been hype and failure. For example, IBM Watson has been criticized for underperforming on its Big Data proclamations, while the promises of Theranos led to fraud charges.

During this panel, we will speak to key leaders from across the industry about how they are helping biopharmas speed up their R&D while making it more accurate, and how to manage expectations against hype.

Andrew Allen M.D., Ph.D.

Co-Founder, President, and CEO // Gritstone Oncology

Percival Barretto-Ko (Opening Remarks)

President, Americas Operations // Astellas

Alexis Borisy

Partner // Third Rock Ventures

Kevin Julian

Senior Managing Director, Life Sciences // Accenture

Daphne Koller

CEO // Insitro

Saurabh Saha

Global Head of Translational Medicine // Bristol-Myers Squibb

John Tsai

Head of Global Drug Development // Novartis

Tony Wood

SVP Medicinal Science and Technology // GSK

Amirah Al Idrus (Moderator)

Editor // FierceBiotech

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title
CHALLENGES AND SOLUTIONS AROUND THE DRUG PRICING DEBATE
9:45AM-11:00AM


 The battle over drug pricing is heating up as the Trump administration rolls out new proposals and the newly Democratic House promises to push such controversial measures as Medicare price negotiation—perhaps with the cooperation of the president. Analysts see continued scrutiny on pricing, plus new Congressional investigations, as threats to pharma over the next couple of years.

But policymakers are also looking at market-based solutions that the industry proponents have also supported, including value-based pricing, sharing rebates with patients at the pharmacy and advancing pro-innovation trade agreements.

We bring together experts and companies on all sides of this debate to talk about the challenges coming over the next few years and potential solutions.

Fritz Bittenbender

Senior Vice President, Government Affairs // Genentech

Ruud Dobber

Executive Vice President, North America // AstraZeneca US

Kristi Martin

Senior Vice President // Waxman Strategies

Glen Stettin, MD

Chief Innovation Officer // Express Scripts

Stephen J. Ubl (Opening Remarks)

President and Chief Executive Officer // PhRMA

Carly Helfand (Moderator)

Senior Editor // FiercePharma

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

sponsors

Pricing

Registration Rate

Attendee: $189

Event is sold out!

location

FAQ

Yes, valet parking is available for an additional fee.

Yes, a full breakfast will be served from 7:00AM-7:45AM

Attendee substitutions may be made on or before January 4, 2019. Please submit a written request by email to events[email protected]

Due to the nature of this event, we are unable to provide refunds. Attendee substitutions may be made on or before January 4, 2019. Please submit a written request by email to [email protected]